830 related articles for article (PubMed ID: 25120191)
21. UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model.
Zhang K; Wang A; Zhong K; Qi S; Wei C; Shu X; Tu WY; Xu W; Xia C; Xiao Y; Chen A; Bai L; Zhang J; Luo B; Wang W; Shen C
Neuron; 2021 Jun; 109(12):1949-1962.e6. PubMed ID: 33991504
[TBL] [Abstract][Full Text] [Related]
22. Bidirectional nucleolar dysfunction in C9orf72 frontotemporal lobar degeneration.
Mizielinska S; Ridler CE; Balendra R; Thoeng A; Woodling NS; Grässer FA; Plagnol V; Lashley T; Partridge L; Isaacs AM
Acta Neuropathol Commun; 2017 Apr; 5(1):29. PubMed ID: 28420437
[TBL] [Abstract][Full Text] [Related]
23. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations.
Mori K; Lammich S; Mackenzie IR; Forné I; Zilow S; Kretzschmar H; Edbauer D; Janssens J; Kleinberger G; Cruts M; Herms J; Neumann M; Van Broeckhoven C; Arzberger T; Haass C
Acta Neuropathol; 2013 Mar; 125(3):413-23. PubMed ID: 23381195
[TBL] [Abstract][Full Text] [Related]
24. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers.
Mackenzie IR; Frick P; Grässer FA; Gendron TF; Petrucelli L; Cashman NR; Edbauer D; Kremmer E; Prudlo J; Troost D; Neumann M
Acta Neuropathol; 2015 Dec; 130(6):845-61. PubMed ID: 26374446
[TBL] [Abstract][Full Text] [Related]
25. Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients.
Mordes DA; Prudencio M; Goodman LD; Klim JR; Moccia R; Limone F; Pietilainen O; Chowdhary K; Dickson DW; Rademakers R; Bonini NM; Petrucelli L; Eggan K
Acta Neuropathol Commun; 2018 Jul; 6(1):55. PubMed ID: 29973287
[TBL] [Abstract][Full Text] [Related]
26. Poly-glycine-alanine exacerbates C9orf72 repeat expansion-mediated DNA damage via sequestration of phosphorylated ATM and loss of nuclear hnRNPA3.
Nihei Y; Mori K; Werner G; Arzberger T; Zhou Q; Khosravi B; Japtok J; Hermann A; Sommacal A; Weber M; ; ; Kamp F; Nuscher B; Edbauer D; Haass C
Acta Neuropathol; 2020 Jan; 139(1):99-118. PubMed ID: 31642962
[TBL] [Abstract][Full Text] [Related]
27. Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers.
Gendron TF; van Blitterswijk M; Bieniek KF; Daughrity LM; Jiang J; Rush BK; Pedraza O; Lucas JA; Murray ME; Desaro P; Robertson A; Overstreet K; Thomas CS; Crook JE; Castanedes-Casey M; Rousseau L; Josephs KA; Parisi JE; Knopman DS; Petersen RC; Boeve BF; Graff-Radford NR; Rademakers R; Lagier-Tourenne C; Edbauer D; Cleveland DW; Dickson DW; Petrucelli L; Boylan KB
Acta Neuropathol; 2015 Oct; 130(4):559-73. PubMed ID: 26350237
[TBL] [Abstract][Full Text] [Related]
28. Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins.
Davidson Y; Robinson AC; Liu X; Wu D; Troakes C; Rollinson S; Masuda-Suzukake M; Suzuki G; Nonaka T; Shi J; Tian J; Hamdalla H; Ealing J; Richardson A; Jones M; Pickering-Brown S; Snowden JS; Hasegawa M; Mann DM
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):242-54. PubMed ID: 26538301
[TBL] [Abstract][Full Text] [Related]
29. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion.
Brettschneider J; Van Deerlin VM; Robinson JL; Kwong L; Lee EB; Ali YO; Safren N; Monteiro MJ; Toledo JB; Elman L; McCluskey L; Irwin DJ; Grossman M; Molina-Porcel L; Lee VM; Trojanowski JQ
Acta Neuropathol; 2012 Jun; 123(6):825-39. PubMed ID: 22426854
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS.
Yamakawa M; Ito D; Honda T; Kubo K; Noda M; Nakajima K; Suzuki N
Hum Mol Genet; 2015 Mar; 24(6):1630-45. PubMed ID: 25398948
[TBL] [Abstract][Full Text] [Related]
31. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of toxicity in C9FTLD/ALS.
Gendron TF; Belzil VV; Zhang YJ; Petrucelli L
Acta Neuropathol; 2014 Mar; 127(3):359-76. PubMed ID: 24394885
[TBL] [Abstract][Full Text] [Related]
33. Cell-to-cell transmission of C9orf72 poly-(Gly-Ala) triggers key features of ALS/FTD.
Khosravi B; LaClair KD; Riemenschneider H; Zhou Q; Frottin F; Mareljic N; Czuppa M; Farny D; Hartmann H; Michaelsen M; Arzberger T; Hartl FU; Hipp MS; Edbauer D
EMBO J; 2020 Apr; 39(8):e102811. PubMed ID: 32175624
[TBL] [Abstract][Full Text] [Related]
34. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions.
Cooper-Knock J; Walsh MJ; Higginbottom A; Robin Highley J; Dickman MJ; Edbauer D; Ince PG; Wharton SB; Wilson SA; Kirby J; Hautbergue GM; Shaw PJ
Brain; 2014 Jul; 137(Pt 7):2040-51. PubMed ID: 24866055
[TBL] [Abstract][Full Text] [Related]
35. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress.
Zhang YJ; Jansen-West K; Xu YF; Gendron TF; Bieniek KF; Lin WL; Sasaguri H; Caulfield T; Hubbard J; Daughrity L; Chew J; Belzil VV; Prudencio M; Stankowski JN; Castanedes-Casey M; Whitelaw E; Ash PE; DeTure M; Rademakers R; Boylan KB; Dickson DW; Petrucelli L
Acta Neuropathol; 2014 Oct; 128(4):505-24. PubMed ID: 25173361
[TBL] [Abstract][Full Text] [Related]
36. NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility.
Gleixner AM; Verdone BM; Otte CG; Anderson EN; Ramesh N; Shapiro OR; Gale JR; Mauna JC; Mann JR; Copley KE; Daley EL; Ortega JA; Cicardi ME; Kiskinis E; Kofler J; Pandey UB; Trotti D; Donnelly CJ
Nat Commun; 2022 Jun; 13(1):3380. PubMed ID: 35697676
[TBL] [Abstract][Full Text] [Related]
37. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum.
Cruts M; Gijselinck I; Van Langenhove T; van der Zee J; Van Broeckhoven C
Trends Neurosci; 2013 Aug; 36(8):450-9. PubMed ID: 23746459
[TBL] [Abstract][Full Text] [Related]
38. Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice.
Peters OM; Cabrera GT; Tran H; Gendron TF; McKeon JE; Metterville J; Weiss A; Wightman N; Salameh J; Kim J; Sun H; Boylan KB; Dickson D; Kennedy Z; Lin Z; Zhang YJ; Daughrity L; Jung C; Gao FB; Sapp PC; Horvitz HR; Bosco DA; Brown SP; de Jong P; Petrucelli L; Mueller C; Brown RH
Neuron; 2015 Dec; 88(5):902-909. PubMed ID: 26637797
[TBL] [Abstract][Full Text] [Related]
39. Expression of C9orf72-related dipeptides impairs motor function in a vertebrate model.
Swaminathan A; Bouffard M; Liao M; Ryan S; Callister JB; Pickering-Brown SM; Armstrong GAB; Drapeau P
Hum Mol Genet; 2018 May; 27(10):1754-1762. PubMed ID: 29528390
[TBL] [Abstract][Full Text] [Related]
40. Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia.
Stepto A; Gallo JM; Shaw CE; Hirth F
Acta Neuropathol; 2014 Mar; 127(3):377-89. PubMed ID: 24366528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
